Related Experiment Video
Updated: Jan 14, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
A novel variant in MYBPC3 causes hypertrophic cardiomyopathy by haploinsufficiency
Yuanyuan Zhang1, Wenyan Gong2, Yusheng Cong3
1Department of Cardiovascular Ultrasonic Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Insights
A new MYBPC3 gene mutation, c.1042_1043insCGGCA, causes familial hypertrophic cardiomyopathy (HCM). This genetic variant leads to reduced cardiac myosin-binding protein C (cMyBP-C) levels, contributing to HCM development.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Genetic Diseases
Background:
- Familial hypertrophic cardiomyopathy (HCM) is a prevalent genetic cardiovascular disease.
- The precise genetic mutations causing HCM hypercontractility and impaired relaxation remain incompletely understood.
Purpose of the Study:
- To identify and confirm a novel variant in the cardiac myosin-binding protein C (cMyBP-C) gene (MYBPC3) within an HCM-affected family.
- To investigate the functional consequences of the identified MYBPC3 variant.
Main Methods:
- Pedigree analysis and clinical data collection.
- DNA extraction and next-generation sequencing for mutation identification.
- Quantitative gene expression (RT-qPCR) and protein level analysis (Western blot) of MYBPC3 and cMyBP-C.
Main Results:
- A novel mutation, c.1042_1043insCGGCA, was identified in the MYBPC3 gene in HCM patients and family members.
- In silico analysis predicted the mutation leads to a premature stop codon and altered protein sequence.
- Significantly reduced MYBPC3 mRNA and cMyBP-C protein expression were observed in HCM hearts compared to controls.
Conclusions:
- The c.1042_1043insCGGCA mutation in MYBPC3 is a newly identified genetic cause of HCM.
- This mutation results in c-MyBP-C haploinsufficiency, contributing to the pathogenesis of HCM.
Background:
Familial hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease (CVD). Related mutations contributing to hypercontractility and poor relaxation in HCM are not completely understood.
Purpose:
This study aimed to explore and verify a novel variant of cardiac myosin-binding protein C (cMyBP-C, encoded by MYBPC3) in an HCM family.
Methods:
Clinical information and cardiac parameters were collected in the pedigree. Genomic DNA was extracted from peripheral blood and second-generation sequencing technology was used to investigate the proband and his family members. Subsequent sequence analysis was performed with DNAMAN software. The cardiac expression levels of MYBPC3 mRNA and cMyBP-C protein were assessed using RT-qPCR and Western blot analysis, respectively.
Results:
Typical interventricular septal thickening was detected in all four HCM patients without left ventricular outflow tract obstruction. The c.1042_1043insCGGCA mutation in MYBPC3 was verified in the proband and family members. In silico analysis of the mutation revealed that c.1042_1043insCGGCA led to a shift in the sequence of nucleotides, creating a premature stop codon at the new reading frame. RT-qPCR analysis of MYBPC3 mRNA revealed a marked reduction in HCM heart compared to the normal controls (P < 0.05). Consistently, Western blot analysis showed significantly reduced expression of cMyBP-C in the pedigree in comparison with the controls (P < 0.05).
Conclusion:
The novel c.1042_1043insCGGCA MYBPC3 mutation is a genetic basis for HCM due to c-MyBP-C haploinsufficiency.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Myocarditis I: Introduction

